A detailed history of Cim, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Cim, LLC holds 35,397 shares of EXEL stock, worth $1.47 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
35,397
Previous 35,092 0.87%
Holding current value
$1.47 Million
Previous $1.55 Million 5.5%
% of portfolio
0.2%
Previous 0.22%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$36.22 - $46.25 $11,047 - $14,106
305 Added 0.87%
35,397 $1.46 Million
Q2 2025

Aug 19, 2025

BUY
$34.13 - $46.26 $1.2 Million - $1.62 Million
35,092 New
35,092 $1.55 Million
Q3 2022

Nov 02, 2022

BUY
$15.68 - $22.27 $47,933 - $68,079
3,057 Added 7.02%
46,590 $783,000
Q2 2022

Jul 11, 2022

BUY
$17.44 - $23.16 $759,215 - $1.01 Million
43,533 New
43,533 $958,000
Q2 2019

Jul 22, 2019

SELL
$18.93 - $24.75 $441,258 - $576,922
-23,310 Closed
0 $0
Q1 2019

May 06, 2019

BUY
$19.6 - $24.76 $456,876 - $577,155
23,310 New
23,310 $555,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $13.4B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Cim, LLC Portfolio

Follow Cim, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cim, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cim, LLC with notifications on news.